Arvinas, Inc. (ARVN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. (“Arvinas” or “the Company”) (NASDAQ: ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Arvinas has violated federal securities laws.
Investigation Details
On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant “from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.” On this news, Arvinas’s stock price fell sharply during intraday trading on November 19, 2024.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Arvinas securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]